Talphera (NASDAQ:TLPH) Trading Down 3.9%

Talphera, Inc. (NASDAQ:TLPH)’s stock price dropped 3.9% during mid-day trading on Tuesday . The stock traded as low as $0.85 and last traded at $0.87. Approximately 106,356 shares changed hands during trading, an increase of 22% from the average daily volume of 87,523 shares. The stock had previously closed at $0.91.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Talphera in a report on Friday, August 16th.

Talphera Price Performance

The business’s fifty day moving average price is $0.93 and its 200-day moving average price is $0.99. The stock has a market capitalization of $13.76 million, a PE ratio of -0.91 and a beta of 0.33.

Talphera (NASDAQ:TLPH) last posted its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. On average, analysts expect that Talphera, Inc. will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera at the end of the most recent reporting period. Institutional investors and hedge funds own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.